arrow
E

Emma Searle

University of Manchester
H指数:14
被引数:1,337

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Ataxia and Balance Disorders Associated with GPRC5D-Directed Therapies in Relapsed/Refractory Multiple Myeloma: A Case Series with Practical Recommendations for Management

共济失调和平衡障碍与GPRC5D靶向疗法在复发/难治性多发性骨髓瘤中的关联:一份病例系列及管理实用建议

2026-10-270
OAAI
Phase 1 dose escalation and expansion trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein SL-172154 (SIRPα-Fc-CD40L) in patients with higher-risk myelodysplastic syndrome or acute myeloid leukemia

I期剂量递增和扩展试验:双特异性CD47抑制剂和CD40激动剂Fc融合蛋白SL-172154(SIRPα-Fc-CD40L)在具有高风险骨髓增生异常综合征或急性髓系白血病患者中的应用

Cancer
IF5.1
2026-10-050
OAAI
Etentamig in Relapsed/Refractory Multiple Myeloma: Pooled Phase 1 Data of an Investigational BCMA Bispecific Antibody

Etentamig 在复发/难治性多发性骨髓瘤中的应用:一种实验性 BCMA 双特异性抗体的合并 1 期数据

Blood
IF23.1
2026-01-010
OA
PRELIMINARY EFFICACY OF BEXMARILIMAB WITH AZACITIDINE IN RELAPSED OR REFRACTORY MDS IN BEXMAB PH1/2 STUDY

BEXMAB PH1/2研究中,培克马利姆单抗联合阿扎胞苷治疗复发或难治性MDS的初步疗效

2025-09-010
PRE
A phase 1, first-in-human, dose-escalation study of JNJ-74856665 (dihydroorotate dehydrogenase inhibitor) alone or in combination in patients with AML or MDS

一项关于JNJ-74856665(二氢乳清酸脱氢酶抑制剂)单药或联合用药治疗AML或MDS患者的1期、首次人体试验、剂量递增研究

2025-07-010
OA
Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations

Bleximenib剂量优化及携带KMT2A和NPM1基因变异的复发/难治性急性白血病患者1期研究的RP2D确定

BLOOD
IF23.1
2024-11-055
PRE
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

Elranatamab治疗复发或难治性多发性骨髓瘤: 2期MagnetisMM-3试验结果

2023-08-15173
OAAI